- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00604422
Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in Detection & Classification of Ulcerative Colitis
Visão geral do estudo
Status
Condições
Descrição detalhada
Ulcerative colitis (UC) is a disorder of unknown origin that may be characterized by acute and chronic inflammation of the colon. The extent of the colonic mucosal inflammation varies among individuals, but the disease almost always involves the rectum. Ulcerative colitis has required evaluation by colonoscopy to determine the extent and severity of the disease. The PillCam platform offers an alternative approach for endoscopic visualization of the colon using capsule endoscopy, a swallowable device which contains imagers, light sources, a power source and a RF transmitter. Advantages of the PillCam platform include the elimination of the need for conscious sedation, the minimally invasive, painless nature of the exam, and the ability to pursue normal daily activities immediately following the procedure . Furthermore, compared to standard colonoscopy, the PillCam platform may be more readily accepted by the subjects, thereby improving subjects' willingness to undergo a diagnostic evaluation of the colon.
The PillCam® SB capsule (formerly M2A® Capsule) that was FDA-approved in August 2001 for small bowel evaluation has been ingested to date by more than 700,000 people worldwide and is well accepted by patients and physicians as well as the professional societies. However, adequate visualization of the colon cannot be achieved with the standard PillCam™ SB capsule because of the anatomical and physiological properties of the colon which are significantly different than the small bowel. Moreover, other issues that limit the evaluation of the colonic mucosa by the standard PillCam™ SB procedure include an unsatisfactory level of colon cleanliness and slow progression of the PillCam™ SB capsule through the colon during the desired examination time. Therefore, the development and introduction of a specially designed, customized colon capsule combined with a dedicated capsule colonoscopy procedure protocol will allow for more efficient evaluation of the colonic mucosa. Further details of the PillCam® Colon Capsule Endoscope (PCCE) can be found in the device description section.
In previous studies, the PillCam colon platform has been shown to be safe and to be able to demonstrate colon polyps and cancers. This study is an extension to a trial evaluating the use of PCCE in ulcerative colitis that has already been completed in Hong Kong (n=40). This study is designed to assess the ability of the capsule to accurately detect inflammatory lesions and thus classifying the extent and severity of disease in subjects with ulcerative colitis in comparison to traditional colonoscopy.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
-
Singapore, Cingapura, 119074
- Department of Medicine, National University Hospital
-
-
-
-
-
Hong Kong, Hong Kong
- Chinese university of Hong Kong, Princes of Walses Hospital
-
-
-
-
-
Taipei, Taiwan
- Department of Internal Medicine & Health Management Center, National Taiwan University Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease
The study population will consist of subjects who fulfill all the inclusion criteria and none of the exclusion criteria.
Descrição
Inclusion Criteria:
- Subjects 18-70
- Suspected or known ulcerative colitis patients
Exclusion Criteria:
- Subject has dysphagia
- Subject has congestive heart failure
- Subject who can not tolerate bowel preparation
- Poor bowel preparation
- Subject has renal insufficiency
- Subject is known or is suspected to suffer from intestinal obstruction.
- Subject has a cardiac pacemaker or other implanted electro-medical devices.
- Subject is pregnant
- Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
- Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.
- Subject has any condition, which precludes compliance with study and/or device instructions.
- Subject suffers from life threatening conditions
- Subject is currently participating in another clinical study
- Subject has constipation (less than 3 bowel movements/week)
- Subject has known slow gastric emptying time
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
A
Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Agreement level between capsule and colonoscopy in classifying colitis into the above (see section 3.1) categories.
Prazo: within 7 days
|
within 7 days
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Number, type and severity of adverse events with both PCCE and standard colonoscopy
Prazo: Within 7 days
|
Within 7 days
|
|
Accuracy parameters for detecting active UC
Prazo: within 7 days
|
within 7 days
|
|
Disease severity scoring index for both PCCE and .standard colonoscopy
Prazo: within 7 days
|
within 7 days
|
|
Colon cleansing level score for both PCCE and standard colonoscopy.
Prazo: within 7 days
|
within 7 days
|
|
Grading of the bubbles interference at the colon for PCCE.
Prazo: Within 7 days
|
Within 7 days
|
|
Percentage of excreted colon capsules
Prazo: Within 7 Days
|
Within 7 Days
|
|
PCCE transit time from ingestion to excretion and colon transit time
Prazo: Within 7 Days
|
Within 7 Days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Josef Sung, Prof., Chinese University of Hong Kong
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- MA-107
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .